reports
- Dave Nicoski
- Ross LaDuke
MTB M&T BANK CORPORATION
XENT INTERSECT ENT INC
WDAY WORKDAY INC. CLASS A
TXRH TEXAS ROADHOUSE INC.
TPRE SIRIUSPOINT LTD
SQ SQUARE INC. CLASS A
SIG SIGNET JEWELERS LIMITED
RVNC REVANCE THERAPEUTICS INC.
RGNX REGENXBIO INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
NGVC NATURAL GROCERS BY VITAMIN COTTAGE INC
NDLS NOODLES & COMPANY
MYL VIATRIS INC.
LMNX LUMINEX CORP
HRTX HERON THERAPEUTICS INC
HAL HALLIBURTON COMPANY
FRGI FIESTA RESTAURANT GROUP INC.
FFNW FIRST FINANCIAL NORTHWEST INC.
EWBC EAST WEST BANCORP INC.
DDD 3D SYSTEMS CORPORATION
BYD BOYD GAMING CORPORATION
ARR ARMOUR RESIDENTIAL REIT INC.
APA.. APA CORP.
RRR RED ROCK RESORTS INC. CLASS A
FMAO FARMERS & MERCHANTS BANCORP INC.
IIIN INSTEEL INDUSTRIES INC.
AAOI APPLIED OPTOELECTRONICS INC.
CAH CARDINAL HEALTH INC.
CENT CENTRAL GARDEN & PET COMPANY
MBUU MALIBU BOATS INC. CLASS A
PETS PETMED EXPRESS INC.
AC ASSOCIATED CAPITAL GROUP
INBK FIRST INTERNET BANCORP
CWH CAMPING WORLD HOLDINGS INC. CLASS A
TVTY TIVITY HEALTH INC.
AOBC SMITH & WESSON BRANDS INC.
BY BYLINE BANCORP
EYE NATIONAL VISION HOLDINGS
SPB SPECTRUM BRANDS HOLDINGS INC.
AVRO AVROBIO
EB EVENTBRITE
MRNA MODERNA INC.
CNR CORNERSTONE BUILDING BRANDS INC
MCFT MASTERCRAFT BOAT HOLDINGS
USX U.S. XPRESS ENTERPRISES
1 director sold after exercising options/sold
A director at Intersect Ent Inc sold after exercising options/sold 29,588 shares at 28.432USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Intersect ENT Reports First Quarter 2018 Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2018. Recent Business Highlights In April 2018, the company announced U.S. commercial availability of SINUVA™ Sinus Implant, a new in-office treatment option for recurrent nasal polyps. Placed during a routine doctor’s office visit under local or topical anesthesia, SINUVA ...
Intersect ENT to Present at Deutsche Bank and Bank of America Merrill ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will present at Deutsche Bank’s 43rd Annual Health Care Conference and at Bank of America Merrill Lynch 2018 Healthcare Conference. The Deutsche Bank Conference presentation is scheduled for May 9, 2018 at 10:40am EDT at the Boston InterContinental Hotel and the Bank of America Merrill Lynch presentation is scheduled for May 16, 2018 at 4:00pm EDT at the Encore at The Wynn in Las Vegas. A webcast of both pr...
Intersect ENT to Report First Quarter 2018 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its first quarter on May 1, 2018. The company expects to issue the release at approximately 4:00 p.m. ET and management will host a conference call at 4:30 p.m. ET that same day. To access the conference call via the internet, go to the "Investor Relations" page of the company's web site at www.int...
Intersect ENT Announces Launch of SINUVAâ„¢ Sinus Implant, a New In-Of...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced U.S. commercial availability of the SINUVA™ (mometasone furoate) Sinus Implant, a new approach to treating nasal polyp disease in adult patients who have had previous sinus surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005249/en/ Placed during a routine doctor’s office visit under...
Intersect ENT Reports Fourth Quarter and Full Year 2017 Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2017. Recent Business Highlights In December 2017, the U.S. Food and Drug Administration (FDA) approved the SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have ...
Intersect ENT to Report Fourth Quarter and Year 2017 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its fourth quarter and year 2017 on February 27, 2018. The company expects to issue the release at approximately 4:00 p.m. ET and management will host a conference call at 4:30 p.m. ET that same day. To access the conference call via the internet, go to the "Investor Relations" page of the company...
Intersect ENT Announces Publication of Randomized Pivotal Study of the...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT) today announced publication of results from a randomized pivotal Phase III study of the company’s SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery. Results were published in the International Forum of Allergy & Rhinology. Placed during a routine physician office visit, SINUVA expands in the sinus cavity and delivers an anti-inflammatory st...
Intersect ENT Reports Preliminary Q4 and Year 2017 Revenue
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the fourth quarter and year ended December 31, 2017. Fourth Quarter and Full Year 2017 Preliminary Revenue Preliminary unaudited revenue for the full year 2017 is expected to be in the range of $96.1 to $96.3 million, an increase of 22% compared to $78.7 million for 2016. Preliminary unaudited ...
Intersect ENT Announces FDA Approval of SINUVAâ„¢ Sinus Implant, a New...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171...
Intersect ENT to Present at the 36th Annual J.P. Morgan Healthcare Con...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), today announced that management will present an overview of the company's business at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 p.m. PT at the Westin St. Francis Hotel. A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at http://www.intersectENT.com. The webcast replay will be available for approximately one month. About Inters...
FDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park F...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the U.S. Food and Drug Administration (FDA) has performed a Pre-Approval Inspection (PAI) of the company’s Menlo Park facility related to the company’s New Drug Application (NDA) for the investigational SINUVA™ Steroid Releasing Sinus Implant. At the conclusion of the inspection, the FDA issued a Form 483 with four inspectional observation...
Intersect ENT to Present at the Piper Jaffray 29th Annual Healthcare C...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company’s business at the 29th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for 4:00pm ET on November 28, 2017, at the Lotte New York Palace in New York City. A replay of the presentation will be available via the investors section of the company’s website at www.intersectENT.com. The webcast replay will be archived for approximately one month...
Intersect ENT Reports Third Quarter 2017 Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2017. Third quarter 2017 revenue was $22.3 million, a 21% increase over the third quarter 2016. Recent Business Highlights In October 2017, the company announced the presentation of the results of RESOLVE II, a pivotal phase III study evaluating the safety an...
Intersect ENT Announces a Pivotal Study Publication of PROPEL® Contou...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT) today announced a pivotal study publication of the second cohort of the prospective, randomized, blinded, multi-center PROGRESS study – a trial to assess the safety and efficacy of the company’s PROPEL® Contour steroid releasing sinus implant when placed in the frontal sinuses, which are located behind the forehead. The study was published in the Journal of the American Medical Association – Otolaryngology-Head & Neck Surgery. The authors conclude...
Intersect ENT to Report Third Quarter 2017 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its third quarter on November 2, 2017. The company expects to issue the release at approximately 4:00 p.m. ET and management will host a conference call at 4:30 p.m. ET that same day. To access the conference call via the internet, go to the "Investor Relations" page of the company's web site at w...
Intersect ENT Announces Presentation of Results from RESOLVE II, a Piv...
MENLO PARK, Calif. & BARCELONA, Spain--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced the first presentation of results from RESOLVE II, a randomized, double-blinded, controlled Phase III clinical trial, which assessed the safety and efficacy of SINUVA™, an investigational steroid releasing sinus implant. The RESOLVE II pivotal study assessed the implant in 300 adult chronic sinusitis patients, all of who...
Intersect ENT Announces Presentation of a Meta-Analysis From Two Rando...
MENLO PARK, Calif. & CHICAGO--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced presentation of a meta-analysis from two randomized studies evaluating the safety and efficacy of SINUVA™, an investigational steroid releasing sinus implant. The two studies evaluated the sinus implant in patients with recurrent and medically refractory nasal polyps. Results of the meta-analysis were presented on Saturday, Septe...
Intersect ENT Reports Second Quarter 2017 Results
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2017. Second Quarter Financial Highlights Second quarter 2017 revenue was $24.0 million, a 24% increase over the second quarter 2016 Second quarter 2017 gross margin was 85% compared to 84% in the second quarter 2016 Second...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.